KR20140125351A - 항-cd98 항체 및 이의 사용 방법 - Google Patents

항-cd98 항체 및 이의 사용 방법 Download PDF

Info

Publication number
KR20140125351A
KR20140125351A KR1020147016959A KR20147016959A KR20140125351A KR 20140125351 A KR20140125351 A KR 20140125351A KR 1020147016959 A KR1020147016959 A KR 1020147016959A KR 20147016959 A KR20147016959 A KR 20147016959A KR 20140125351 A KR20140125351 A KR 20140125351A
Authority
KR
South Korea
Prior art keywords
antibody
cancer
seq
human
functional fragment
Prior art date
Application number
KR1020147016959A
Other languages
English (en)
Korean (ko)
Inventor
쟌 립핀코트
데르 호르스트 에드워드 테인 턴 반
죠셉 자크위자
호앙 트란
Original Assignee
이제니카 바이오테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이제니카 바이오테라퓨틱스, 인크. filed Critical 이제니카 바이오테라퓨틱스, 인크.
Publication of KR20140125351A publication Critical patent/KR20140125351A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020147016959A 2011-11-23 2012-11-21 항-cd98 항체 및 이의 사용 방법 KR20140125351A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161563443P 2011-11-23 2011-11-23
US61/563,443 2011-11-23
PCT/US2012/066347 WO2013078377A1 (fr) 2011-11-23 2012-11-21 Anticorps anti-cd98 et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
KR20140125351A true KR20140125351A (ko) 2014-10-28

Family

ID=47295209

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147016959A KR20140125351A (ko) 2011-11-23 2012-11-21 항-cd98 항체 및 이의 사용 방법

Country Status (15)

Country Link
EP (1) EP2782935A1 (fr)
JP (1) JP2015501639A (fr)
KR (1) KR20140125351A (fr)
CN (1) CN104302669A (fr)
AU (1) AU2012340623A1 (fr)
BR (1) BR112014012590A8 (fr)
CA (1) CA2856873A1 (fr)
HK (1) HK1202877A1 (fr)
IL (1) IL232755A0 (fr)
MX (1) MX2014006272A (fr)
PH (1) PH12014501164A1 (fr)
RU (1) RU2014124530A (fr)
SG (1) SG11201402619VA (fr)
WO (1) WO2013078377A1 (fr)
ZA (1) ZA201403760B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2858350A1 (fr) 2011-01-14 2013-07-19 The Regents Of The University Of California Anticorps therapeutiques contre la proteine ror-1 et leurs methodes d'utilisation
US10781259B2 (en) 2013-06-06 2020-09-22 Magenta Therapeutics, Inc. Modified antibodies and related compounds, compositions, and methods of use
WO2014197871A2 (fr) * 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Conjugués anticorps-médicament, compositions et méthodes d'utilisation correspondantes
JP2017114763A (ja) * 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
SG11201703750XA (en) * 2014-12-10 2017-06-29 Genentech Inc Blood brain barrier receptor antibodies and methods of use
LT3336185T (lt) * 2015-08-10 2022-02-10 Osaka University Antikūnas
CN105385694B (zh) * 2015-11-20 2019-01-18 中国人民解放军第四军医大学 抗人cd98单克隆抗体98-3h3轻、重链可变区基因及其应用
WO2017214462A2 (fr) * 2016-06-08 2017-12-14 Abbvie Inc. Anticorps anti-cd98 et conjugués anticorps-médicament
JP6751165B2 (ja) 2016-06-08 2020-09-02 アッヴィ・インコーポレイテッド 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
AU2017277914A1 (en) * 2016-06-08 2019-01-03 Abbvie Inc. Anti-CD98 antibodies and antibody drug conjugates
EP3468599A2 (fr) * 2016-06-08 2019-04-17 AbbVie Inc. Anticorps anti-cd98 et conjugués anticorps-médicament
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
EP3715370A1 (fr) * 2019-03-28 2020-09-30 Technische Universität München Anticalines haute affinité dirigées contre des cd98hc humains
JP2023520811A (ja) * 2020-04-08 2023-05-19 アリアダ セラピューティクス，インコーポレイテッド 抗ｃｄ９８抗体およびその使用
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
EP4347646A1 (fr) * 2021-06-02 2024-04-10 Huahui Health Ltd. Anticorps anti-cd98 et leurs utilisations
WO2023100829A1 (fr) 2021-11-30 2023-06-08 第一三共株式会社 Anticorps musc dégradable par la protéase
WO2023109956A1 (fr) * 2021-12-17 2023-06-22 Biocytogen Jiangsu Co., Ltd. Animal non humain génétiquement modifié comportant un cd98hc humain ou chimérique
KR20240141757A (ko) 2022-02-09 2024-09-27 다이이찌 산쿄 가부시키가이샤 환경 응답성 마스킹 항체 및 그 이용

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
DE69334351D1 (de) 1992-02-06 2011-05-12 Novartis Vaccines & Diagnostic Biosynthetisches Bindeprotein für Tumormarker
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1141024B1 (fr) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRENANT UNE VARIANTE DE LA REGION Fc DE L'IgG1 HUMAIN
EP1197755A1 (fr) 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification de sites de liaison de protéines
CA2462113C (fr) 2001-10-01 2013-01-29 Dyax Corp. Vecteurs d'affichage eukaryotes multichaine et leurs utilisations
US20040005709A1 (en) 2001-10-24 2004-01-08 Hoogenboom Henricus Renerus Jacobus Mattheus Hybridization control of sequence variation
CA2488441C (fr) 2002-06-03 2015-01-27 Genentech, Inc. Bibliotheques de phages et anticorps synthetiques
WO2005044853A2 (fr) 2003-11-01 2005-05-19 Genentech, Inc. Anticorps anti-vegf
RU2412947C2 (ru) 2004-09-23 2011-02-27 Дженентек, Инк. Антитела, сконструированные на основе цистеинов, и их конъюгаты
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007044515A1 (fr) 2005-10-07 2007-04-19 Exelixis, Inc. Inhibiteurs de mek et procedes pour les utiliser
TWI390034B (zh) 2006-04-06 2013-03-21 Kyowa Hakko Kirin Co Ltd Novel anti-CD98 antibody
GB0615662D0 (en) * 2006-08-07 2006-09-13 Affitech As Antibody
WO2011118804A1 (fr) * 2010-03-26 2011-09-29 国立大学法人徳島大学 Nouvel anticorps anti-cd98 et son utilisation

Also Published As

Publication number Publication date
ZA201403760B (en) 2017-09-27
HK1202877A1 (en) 2015-10-09
JP2015501639A (ja) 2015-01-19
SG11201402619VA (en) 2014-10-30
BR112014012590A2 (pt) 2017-06-20
CN104302669A (zh) 2015-01-21
EP2782935A1 (fr) 2014-10-01
NZ626513A (en) 2017-02-24
WO2013078377A1 (fr) 2013-05-30
BR112014012590A8 (pt) 2017-12-19
AU2012340623A1 (en) 2014-07-17
PH12014501164A1 (en) 2014-10-20
WO2013078377A9 (fr) 2013-08-08
IL232755A0 (en) 2014-07-31
CA2856873A1 (fr) 2013-05-30
MX2014006272A (es) 2014-10-24
RU2014124530A (ru) 2015-12-27

Similar Documents

Publication Publication Date Title
KR20140125351A (ko) 항-cd98 항체 및 이의 사용 방법
EP3950716A1 (fr) Anticorps anti-claudine 18.2 et utilisation associée
CN104710532B (zh) 人源化的抗-β7拮抗剂及其应用
JP5710487B2 (ja) 抗ｎｏｔｃｈ２抗体および使用方法
US20150231240A1 (en) Anti-c16orf54 antibodies and methods of use thereof
CN107108740A (zh) 抗fgfr2/3抗体及其使用方法
JP2018506961A (ja) 抗Ａｘｌアンタゴニスト抗体
TW200825105A (en) Antibodies and immunoconjugates and uses therefor
AU2007226522B2 (en) Antibodies to EGFL7 and methods for their use
CA3058267C (fr) Compositions et procedes de detection et de traitement du cancer de la prostate a l'aide d'une molecule de liaison de progastrine
WO2015161247A1 (fr) Anticorps anti-c16orf54 humanisés et leurs méthodes d'utilisation
JP2022539344A (ja) 抗ｃｅａ抗体及びその応用
CA3058265C (fr) Compositions et methodes de traitement du cancer du poumon
CN114787187B (zh) 抗cxcr2抗体及其应用
EP4070816A1 (fr) Anticorps anti-gdf15
KR20180054818A (ko) 암 줄기세포의 저해를 위한 조성물 및 방법
US20230041071A1 (en) Antibodies against areg and its use
TWI429655B (zh) 抗egfl7抗體、包含其之組合物、編碼其之多核苷酸及其製造及使用方法
NZ626513B2 (en) Anti-cd98 antibodies and methods of use thereof
CN113710701A (zh) 抗fgf19抗体

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid